Endocrine Abstracts

Introduction: Vasopression-2 receptor antagonists (VPAs) have been licensed for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). As usage extends to other causes of hyponatraemia, over-rapid correction and hypernatraemia remains as important side-effect. We present a patient with severe SIADH highlighting the need for guidance and vigilance when using these potent drugs.Case: A 82-year-old lady...